Meeting
2022 ASCO Annual Meeting
Post-treatment detection of circulating methylated BCAT1 and IKZF1 as prognostic indicators for recurrence in patients with colorectal cancer.
Authors
Graeme P. Young
Flinders University, Adelaide, SA, Australia
Graeme P. Young , Erin L. Symonds , Amitesh Chandra Roy , Kathryn J Cornthwaite , Lawrence Charles LaPointe , Susanne Kartin Pedersen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
12611000318987
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3575)
DOI
10.1200/JCO.2022.40.16_suppl.3575
Abstract #
3575
Poster Bd #
369
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical performance of methylation-based liquid biopsy test COLVERA after optimization of test interpretation rules.
First Author: Zivjena Vucetic
Poster
2018 ASCO Annual Meeting
A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival.
First Author: David Murray
Poster
2017 ASCO Annual Meeting
Circulating tumor DNA analysis before and after resection for colorectal cancer.
First Author: Erin L. Symonds
Poster
2016 Gastrointestinal Cancers Symposium
A novel 2-gene blood test for colorectal cancer recurrence.
First Author: Susanne Kartin Pedersen